Every brighter tomorrow begins with a spark of hope. 🪔✨
May this Festival of Lights bring renewed hope, happiness, and brighter beginnings to you and your loved ones.
Wishing you a Happy and Prosperous Diwali from all of us at Actorius!
#HappyDiwali#Diwali2026#Actorius
CAMO 2026 | Cancer in Motion
Actorius & ACTREC brought global experts together to advance precision oncology, featuring the launch of OncoDiscover® NGS & TDM.
#CAMO2026#Actorius#ACTREC@ACTREC_TMC
#Actorius Genetics Laboratory | Pune
Inaugurated by Liquid Biopsy pioneers Dr. Catherine Alix-Panabières and Dr. Klaus Pantel, our new Genetics Laboratory strengthens Actorius’ capabilities in NGS and CDSCO-approved #OncoDiscover® CTC testing, advancing precision oncology.
This #Dussehra, we celebrate the triumph of light over darkness and continue to believe in the power of science, discovery, and early insight to move cancer care forward.
In Cancer Care, Early is Everything.
Wishing you and your loved ones a happy and meaningful Dussehra.
Every breast cancer journey is different. Understanding how cancer changes over time matters.
OncoDiscover® uses circulating tumour cells (CTCs) from a blood sample to provide complementary insights for cancer monitoring and treatment follow-up.
Because Early is Everything.
Behind every cancer journey is the need to understand how disease changes over time. This World Lymphoma Awareness Day, liquid biopsy and CTC research are expanding insights into cancer biology and monitoring through a simple blood sample.
#LymphomaAwareness#LiquidBiopsy#CTC
Reflections from FHNO 2026 | Kashmir
Amid the silent valleys of Kashmir and the soothing waves of Dal Lake, FHNO 2026 created a meaningful space for conversations, collaboration, and shared perspectives on the future of oncology.
A memorable few days of science, collaboration, and inspiring conversations in the beautiful setting of Kashmir.
Together, advancing oncology. Together, shaping a better future for cancer care.
Beyond EpCAM. Capture the EMT Phenotype.
Introducing OncoDiscover® EMT CTC — an approach designed to identify and characterize EMT-associated circulating tumour cells (CTCs) and bring an additional dimension to CTC phenotyping.
This approach enables characterization of mesenchymal and hybrid CTC phenotypes, providing an additional dimension for studying the phenotypic heterogeneity of circulating tumour cells and their association with tumour invasion and dissemination.
Ovarian cancer demands more than a snapshot in time. Liquid biopsy and CTC research are expanding possibilities for cancer monitoring through blood-based insights.
This #OvarianCancerAwarenessMonth, let’s support awareness, research & informed cancer care
#Actorius#OncoDiscover